Press "Enter" to skip to content

New Drug May Prevent Brain Against Memory Loss In Alzheimer’s Disease

Recently, in the study collaboration amid the Tetra Therapeutics and the UB (University at Buffalo) a new drug was discovered that might guard against nerve damage, memory loss, and other symptoms of Alzheimer’s disease. The preclinical research discovered that the drug known as BPN14770 impedes the impacts of amyloid-beta, which is a trademark protein of Alzheimer’s disease that is harmful to nerve cells. The new studies find Alzheimer’s disease might advance without dementia in about 25% of healthy 80-Years-old patients, indicating the body might turn to offsetting mechanisms to uphold the nervous system. BPN14770—which is under development by Tetra Therapeutics—can assist in activating these mechanisms that maintain nerve health and preclude dementia, even with the advancement of Alzheimer’s disease. The research was published in the Journal of Pharmacology and Experimental Therapeutics.

Its benefits can also decode the developmental disabilities, Fragile X syndrome, and schizophrenia, researchers say. Ying Xu—Research Associate Professor at the UB—said, “Such findings entail that Alzheimer’s disease pathology can be abided by the brain to some extent owing to offsetting mechanisms functioning at the synaptic and cellular levels. Our new study indicates that BPN14770 might be able to activate multiple biological methods that prevent the brain from neuronal damage, memory deficits, and biochemical impairments.”

On a similar note, recently, scientists identified the potential new target to battler with Alzheimer’s disease. The researchers at the Temple University’ LKSOM (Lewis Katz School of Medicine) now showed that in Alzheimer’s disease, mitochondrial calcium transport remodeling—which is an attempt by cells to balance for flagging metabolic dysfunction and energy production—is initially beneficial and in the end becomes maladaptive, increasing the declines in mitochondrial memory, function, and learning. The new study was published in the journal Nature Communications.

David Fortier
Author Details
EDITOR-IN-CHIEF At Daily News Gazette 24

David Fortier is active in the field of Health from the last 10 years. After completing his Bachelor’s Degree in Medicines, he concentrated on practicing in his field and offering the best possible health care to all patients. However, he was attracted by the enormous power of the Daily News Gazette 24 platform to connect with and educate an immense population. So, to share his knowledge and offer tips to maintain a healthy lifestyle, David is connected with the Daily News Gazette 24 platform from the last 6 years. Furthermore, he believes in communicating with people and consistently advancing his writing skills to provide the Daily News Gazette 24 readers with diverse recent topics in the Health domain.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *